No, you should not receive the shingles vaccine during an active herpes zoster outbreak.
The shingles vaccine should be deferred until the acute outbreak has completely resolved—specifically, wait until all lesions have dried and crusted, or if only non-crusting lesions are present, until no new lesions appear within a 24-hour period.
Timing of Vaccination After Active Outbreak
The evidence consistently supports waiting after an active herpes zoster episode before administering the vaccine:
- Minimum waiting period: At least 2 months after the acute episode has resolved 1
- Rationale: This allows the acute inflammatory process to subside and ensures the immune system has returned to baseline
Different international guidelines vary slightly in their recommendations, ranging from waiting until symptoms abate (US, Germany) to 2 months (Austria) to up to 1 year (Canada, Ireland, Australia) 1. However, the 2-month minimum is based on documented evidence that recurrence of herpes zoster does not occur before 2 months after an initial episode 1.
Why Vaccination After Recovery Is Still Recommended
Despite having had a recent outbreak, vaccination remains important because:
- Recurrence rates are substantial: The cumulative incidence of herpes zoster recurrence reaches 2.5% at 2 years, 6.6% at 6 years, and 10.3% at 10 years 1
- Vaccine effectiveness is maintained: Studies show that zoster vaccine administered 6-12 months after an outbreak provides similar immunogenicity compared to vaccination 1-5 years later 2
- Both vaccine types boost immunity: Whether you receive the live attenuated vaccine (Zostavax) or the recombinant vaccine (Shingrix), both significantly increase VZV IgG concentrations and T-cell responses after prior herpes zoster 2
Practical Algorithm for Vaccination Timing
During active outbreak: Do NOT vaccinate
- Wait until all vesicular lesions have completely dried and crusted
- If only macular/papular lesions present, wait until no new lesions for 24 hours 3
After outbreak resolution: Wait minimum 2 months 1
Proceed with vaccination: Either recombinant zoster vaccine (Shingrix, preferred) or live attenuated vaccine (Zostavax) if age-appropriate and not immunocompromised
Special Considerations
For immunocompromised patients (including those on immunosuppressive therapy for inflammatory bowel disease, rheumatologic conditions, or other autoimmune diseases):
- The recombinant vaccine (Shingrix) is strongly preferred as it is non-live and safe in immunosuppressed individuals 4, 5
- Live attenuated vaccine (Zostavax) is contraindicated during immunosuppressive therapy 4, 6
- If using live vaccine, it must be given at least 4 weeks before starting immunosuppressive medications 4, 5
Common pitfall to avoid: Do not confuse the timing recommendations for vaccination after an outbreak with the contraindication during an active outbreak. The vaccine is not used to treat active disease or prevent postherpetic neuralgia in ongoing cases 7.
The recombinant zoster vaccine (Shingrix) is now the preferred vaccine for adults ≥50 years, showing 90-97% efficacy compared to 50-70% for the live vaccine 8, 9, and can be safely administered to immunocompromised patients after the acute outbreak has resolved.